Market Research Logo

Global Type 1 Diabetes Market 2016-2020

Global Type 1 Diabetes Market 2016-2020

About Type 1 Diabetes Drugs

Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:

  • Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
  • Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
  • Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the body’s ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

Technavio’s analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Sanofi SA
Other prominent vendors
  • Adocia
  • Astellas Pharma
  • AstraZeneca
  • Baxalta
  • BHV Pharma
  • Biocon
  • Biodel
  • Boehringer Ingelheim
  • CureDM
  • Dance Biopharm
  • Diamyd Therapeutics AB
  • Diasome Pharmaceuticals
  • DiaVac
  • Exsulin
  • Gan & Lee Pharmaceuticals
  • Generex Biotechnology
  • GlaxoSmithKline
  • ILTOO Pharma
  • Intrexon
  • Islet Sciences
  • Kamada
  • Kotobuki Pharmaceutical
  • Lexicon Pharmaceuticals
  • Living Cell Technologie
  • MacroGenics
  • MannKind Pharmaceuticals
  • Merck
  • Merrion Pharmaceutical
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Perle Biosciences
  • Pfizer
  • REGiMMUNE
  • Strongbridge Biopharma
  • Toleranzia
  • Tolerio
  • Xeris Pharmaceuticals
  • XOMA
Market driver
  • Increase in prevalence of type 1 diabetes
  • For a full, detailed list, view our report
Market challenge
  • Poor storage conditions and distribution policies for insulin
  • For a full, detailed list, view our report
Market trend
  • Awareness programs and initiatives
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Type 1 Diabetes Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Type 1 Diabetes Drugs Market: Eli Lilly and Company, Novo Nordisk A/S, and Sanofi SA.

Other Prominent Vendors in the market are: Adocia, Astellas Pharma, AstraZeneca, Baxalta, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, CureDM, Dance Biopharm, Diamyd Therapeutics AB, Diasome Pharmaceuticals, DiaVac, Exsulin, Gan & Lee Pharmaceuticals, Generex Biotechnology, GlaxoSmithKline, ILTOO Pharma, Intrexon, Islet Sciences, Kamada, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Living Cell Technologie, MacroGenics, MannKind Pharmaceuticals, Merck, Merrion Pharmaceutical, Oramed Pharmaceuticals, Osiris Therapeutics, Perle Biosciences, Pfizer, REGiMMUNE, Strongbridge Biopharma, Toleranzia, Tolerio, Xeris Pharmaceuticals, and XOMA.

Commenting on the report, an analyst from Technavio’s team said: “The increased awareness about type 1 diabetes will replicate itself in terms of the rise in the number of people opting for the treatment. National and international awareness campaigns worldwide focus on enhancing diabetes-related knowledge and its management.”

According to the report, an increase in the type 1 diabetes population is expected to increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The market for type 1 diabetes drugs is served by insulin-based replacement products, including regular insulin and insulin analogs. Chemically, insulin-based products can be categorized into animal insulin, recombinant human insulin, and insulin analogs.

Further, the report states that besides the high prices and accessibility of insulin-based therapies, the products also have poor storage and distribution policies. Inadequate distribution policies and the lack of a centralized supply chain lead to price variations between countries.

Companies Mentioned

Eli Lilly and Company, Novo Nordisk A/S, Sanofi SA, Adocia, Astellas Pharma, AstraZeneca, Baxalta, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, CureDM, Dance Biopharm, Diamyd Therapeutics AB, Diasome Pharmaceuticals, DiaVac, Exsulin, Gan & Lee Pharmaceuticals, Generex Biotechnology, GlaxoSmithKline, ILTOO Pharma, Intrexon, Islet Sciences, Kamada, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Living Cell Technologie, MacroGenics, MannKind Pharmaceuticals, Merck, Merrion Pharmaceutical, Oramed Pharmaceuticals, Osiris Therapeutics, Perle Biosciences, Pfizer, REGiMMUNE, Strongbridge Biopharma, Toleranzia, Tolerio, Xeris Pharmaceuticals, XOMA.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria for type 1 diabetes drugs
  • Disease overview
    • Introduction
    • Risk factors
    • Diagnosis
      • Table Diagnostic test for diabetes based on blood sugar levels
      • Table Diagnostic test for diabetes based on glycated hemoglobin levels
    • Management
    • Epidemiology
    • Economic burden
  • Insulin: An overview
    • Product portfolio
    • Global human insulin market
      • Table Global human insulin market 2015-2020 ($ billions)
  • Pipeline analysis
    • Table Pipeline portfolio: Global type 1 diabetes drugs market
    • Faster-acting insulin aspart (NN1218)
    • Farxiga/Forxiga
    • SAR342434
    • NN9211
    • LY2605541
    • Sotagliflozin
    • MK-1293
    • PRL001
    • Otelixizumab
  • Reimbursement scenario in US
  • Market landscape
    • Global diabetes drugs market
      • Table Global diabetes drugs market by type of disease prevalence 2015
      • Table Top-selling diabetes drugs based on sales 2014 ($ billions)
      • Table Market share of global diabetes drugs in global pharmaceutical drugs market 2015
      • Table Global diabetes drugs market 2015-2020 ($ billions)
      • Table Market share analysis of vendors in global diabetes drugs market 2015
    • Global type 1 diabetes drugs market
      • Table Global type 1 diabetes drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Segmentation of type 1 diabetes drugs market by drug class
    • Insulin
    • Others
      • Table Estimated market share of global type 1 diabetes drugs market by drug class 2020
  • Geographical segmentation
    • Table Segmentation of global type 1 diabetes drugs market based on geography 2015
    • Table Type 1 diabetes drugs market revenue by geography 2015-2020 ($ billions)
    • Table Global type 1 diabetes drugs market by geography 2015-2020
    • Type 1 diabetes drugs market in Americas
      • Table Type 1 diabetes drugs market in Americas 2015-2020 ($ billions)
    • Type 1 diabetes drugs market in EMEA
      • Table Type 1 diabetes drugs market in EMEA 2015-2020 ($ billions)
    • Type 1 diabetes drugs market in APAC
      • Table Type 1 diabetes drugs market in APAC 2015-2020 ($ billions)
      • Table Global type 1 diabetes drugs market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increase in prevalence of type 1 diabetes
    • Advances in insulin delivery technology
    • Rise in price of insulin drugs
    • Stringent regulatory conditions for biosimilar drugs
    • Promising drug pipeline
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Side effects of current therapies
    • Fierce market competition
    • Poor storage conditions and distribution policies for insulin
    • Gap in nation-level diabetes management plans
    • Rising concerns in scientific community
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Development of drugs with novel mechanisms
    • Awareness programs and initiatives
    • Focus on emerging markets
    • Increase in academia-industry collaboration
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2015
      • Table Revenues from sales of major products in type 1 diabetes market 2012-2014 ($ billions)
    • Novo Nordisk
      • Table Novo Nordisk: Business segmentation by revenue 2015
      • Table Novo Nordisk: R&D expenditure 2015
      • Table Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions)
      • Table Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions)
      • Table Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions)
      • Table Novo Nordisk: Geographical split of revenues of NovoRapid/NovoLog, 2015
      • Table Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions)
      • Table Novo Nordisk: Geographical split of revenues of NovoMix/NovoLog Mix, 2015
      • Table Novo Nordisk: YoY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions)
      • Table Novo Nordisk: Key takeaways
    • Sanofi
      • Table Sanofi: Business segmentation by revenue 2015
      • Table Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
      • Table Sanofi: Lantus geographical segmentation by revenue 2015
      • Table Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
      • Table Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
      • Table Sanofi: Key takeaways
    • Eli Lilly
      • Table Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
      • Table Eli Lilly: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report